Le Lézard
Classified in: Ebola virus, Covid-19 virus

Emerging Infectious Disease Global Market Trends 2022 - ResearchAndMarkets.com


The "Emerging Infectious Disease Market Trends, 2022" report has been added to ResearchAndMarkets.com's offering.

The search for the next large-scale emerging disease was on before the COVID-19 pandemic. Respiratory diseases were among those suggested by Kalorama Information and other outlets and medical associations as possibilities for the next threat. The search is constant and is by no means limited to respiratory epidemics.

As the recent monkeypox concern has demonstrated, little-known pathogens can emerge and become large health threats. This necessitates the development of tests at laboratories. For business planners, it's worthwhile to have a resource describing the possible next pathogens of serious concern.

Emerging Infectious Disease Market Trends, 2022 is designed to provide a substantial look at Emerging Infectious Disease Trends with market numbers for significant categories.

This report includes:

Why is it important to examine the world of emerging infectious diseases? In a 2015 TED Talk, Microsoft creator Bill Gates warned that there was a lack of preparation for a viral epidemic. He predicted that it would be "microbes, not missiles" that would cause significant harm to humans. Now with a global focus on testing, Kalorama's update on all of the other diseases that could spread widely seems relevant. It's not to say that every disease will be like the COVID-19 pandemic - not all will be respiratory threats that can spread quickly. Some pathogens spread through contact or insect vectors, slower but often steadier pattern. Vector-based tests such as Zika and malaria remain worrying and new diseases through that transmission method are troubling. And non-respiratory diseases such as Ebola can still spread quickly from person to person if not tested for and treated quickly.

Fortunately, the IVD industry is ready and companies have the capacity to identify antigen targets and viral or bacterial RNA to be able to build high-sensitivity diagnostic products and produce tests at an ever-increasing rate. This report covers their efforts with existing emerging diseases.

Key Topics Covered:

Chapter 1: Executive Summary

Chapter 2: Discussion: The State of Emerging Infectious Diseases

Chapter 3: Viruses

Chapter 4: Bacterial Infections

Chapter 6: Tick-Borne Disease

Chapter 7: Other Emerging Infectious Diseases

Chapter 8: Markets for Major Emerging Infectious Diseases

Chapter 9: Products on the Market

For more information about this report visit https://www.researchandmarkets.com/r/2atvb9.


These press releases may also interest you

at 11:50
The "Global Live Events Market (2024 Edition): Analysis By Event Type (Music, Sports, Comedy, and Theater), By Revenue Source, By Age Group, By Region, By Country: Market Insights and Forecast (2020-2030)" report has been added to...

at 11:31
The FLCCC Alliance today announced Lynne Kristensen will step into the newly created senior director, communications role leading global public relations and media strategy for the organization. She will also oversee the FLCCC's new international...

at 11:30
The OLB Group, Inc., , a diversified Fintech eCommerce merchant services provider and cryptocurrency mining enterprise, announced today that it has received a written letter from Nasdaq, which has determined that for the last 10 consecutive business...

at 10:50
The "India Embedded Finance Business and Investment Opportunities Databook - 75+ KPIs on Embedded Lending, Insurance, Payment, and Wealth Segments - Q1 2024 Update" report has been added to ResearchAndMarkets.com's offering. Embedded Finance...

at 09:55
Egon Zehnder, the world's preeminent leadership advisory firm, today announced Francesco Buquicchio as its next CEO. Buquicchio succeeds Edilson Camara, following a strategic leadership transition and succession planning process. Camara, who will...

at 09:30
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Atara...



News published on and distributed by: